BioStem Technologies, Inc. BSEM
- Market cap
- $69.2M
- P/E
- 0.0×
Follow BSEM
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 7.00 | 2.81 | 0.11 | 0.01 | 0.15 | 0.80 | 1.20 | 4.41 | 3.09 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 17.50 | 14.25 | 13.15 | 3.45 | 3.00 | 1.85 | 4.34 | 7.00 | 28.26 | 19.28 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Emp | |||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | (0.57) | 1.95 | (0.39) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 14 | 16 | (8) |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 0.00% |
ROA
|
|||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 0.00% |
ROE
|
|||
BioStem Technologies, Inc. (BSEM) Latest News
18 Sep
BioStem Technologies, Inc. (BSEM) secures up to $40 million in a committed equity facility. The $40 million equity facility supplies major capital that bolsters financial flexibility and growth capacity.
4 Sep
BioStem Technologies expands hospital access for VENDAJE® and VENDAJE AC® through contracts with Vizient and Premier. Vizient and Premier contracts open major hospital distribution channels for core products and support revenue growth.
21 Aug
BioStem Technologies pursues surgical growth and manufacturing shift following BioTissue deal. BioTissue deal drives BioStem surgical expansion and manufacturing changes with major strategic impact.
13 Aug
BioStem Technologies Inc reported Q2 2026 revenue surging to $7 million during its earnings call. Revenue surge to $7 million demonstrates strong financial momentum that can materially boost investor sentiment and company trajectory.
BioStem Technologies discussed Q2 financial performance, operational updates and future outlook during its earnings call. Q2 earnings call reveals financial results and outlook that can moderately affect near-term market sentiment and valuation.
12 Aug
BioStem Technologies reported a Q2 loss while beating revenue estimates. Q2 loss offset by revenue beat creates mixed quarterly results with moderate effect on near-term stock sentiment.
BioStem Technologies reported its second quarter 2026 financial results. Quarterly results release supplies performance data that shapes near-term investor views.
6 Aug
BioStem Technologies, Inc. (BSEM) announces uplisting to Nasdaq. Nasdaq uplisting boosts liquidity, visibility and institutional access for BioStem Technologies.
BioStem Technologies, Inc. (BSEM) announces its uplisting to Nasdaq. Nasdaq uplisting boosts visibility, liquidity and investor access for BSEM.
10 Jul
BioStem Technologies, Inc. (BSEM) publicly files Form 10 Registration Statement with the Securities and Exchange Commission. Form 10 filing establishes SEC reporting status that improves transparency and may support future market access.
8 Jul
BioStem Technologies, Inc. (BSEM) has been issued four U.S. Design Patents covering fenestrated human placental allograft technologies. Four design patents add intellectual property protection around core allograft technologies that may support product positioning without fundamentally shifting company trajectory.
9 Jun
BioStem Technologies appoints three new board members while keeping Nasdaq uplisting as a key objective. Board additions support governance improvements tied to uplisting plans.
22 May
BioStem Technologies, Inc. (BSEM) raises $2.5 million through private placement financing from its first institutional investor. The financing strengthens liquidity and adds institutional credibility yet supplies only modest capital without signaling major strategic or operational changes.
15 May
BioStem Technologies Inc (BSEM) reported Q1 2026 earnings and announced a strategic acquisition. Strategic acquisition represents major move likely to alter company trajectory.
BioStem Technologies Q1 earnings call highlighted company performance and operations. Q1 earnings call reveals financial results that may influence near-term market views.
14 May
BioStem Technologies, Inc. reported its first quarter 2026 financial results. Quarterly financial results supply data that can shift near-term stock valuation and sentiment.